Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $228,920 | 8 | 100.0% |
| Food and Beverage | $16.40 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $227,631 | 5 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $1,289 | 3 | $0 (2022) |
| Vanda Pharmaceuticals Inc. | $16.40 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,082 | 1 | Regeneron Pharmaceuticals, Inc. ($1,082) |
| 2021 | $17,725 | 5 | Eli Lilly and Company ($17,517) |
| 2020 | $210,114 | 2 | Eli Lilly and Company ($210,114) |
| 2019 | $16.40 | 1 | Vanda Pharmaceuticals Inc. ($16.40) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/15/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $1,081.53 | Research |
| Study: A PHASE 2 STUDY TO ASSESS THE VIROLOGIC EFFICACY OF REGN10933+REGN10987 ACROSS DIFFERENT DOSE REGIMENS IN OUTPATIENTS WITH SARS-COV-2 INFECTION | ||||||
| 09/24/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $20.79 | Research |
| Study: A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | ||||||
| 07/09/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $186.35 | Research |
| Study: A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | ||||||
| 05/18/2021 | Eli Lilly and Company | — | — | In-kind items and services | $1,014.26 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | ||||||
| 01/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $4,597.14 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 01/11/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $11,906.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 09/21/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $209,441.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 07/30/2020 | Eli Lilly and Company | — | — | In-kind items and services | $672.59 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 01/31/2019 | Vanda Pharmaceuticals Inc. | Hetlioz (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Non-24-Hour Sleep-Wake Disorder | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $226,617 | 4 |
| A PHASE 2 STUDY TO ASSESS THE VIROLOGIC EFFICACY OF REGN10933+REGN10987 ACROSS DIFFERENT DOSE REGIMENS IN OUTPATIENTS WITH SARS-COV-2 INFECTION | Regeneron Pharmaceuticals, Inc. | $1,082 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $1,014 | 1 |
| A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | Regeneron Pharmaceuticals, Inc. | $207.14 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 2 | 48 | 58 | $7,395 | $5,195 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 24 | 24 | $3,120 | $2,757 | 88.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 24 | 34 | $4,275 | $2,438 | 57.0% |
About Dr. Roxana Stoici, MD
Dr. Roxana Stoici, MD is a Family Medicine healthcare provider based in St Petersburg, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1639372253.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roxana Stoici, MD has received a total of $228,936 in payments from pharmaceutical and medical device companies, with $1,082 received in 2022. These payments were reported across 9 transactions from 3 companies. The most common payment nature is "" ($228,920).
As a Medicare-enrolled provider, Stoici has provided services to 48 Medicare beneficiaries, totaling 58 services with total Medicare billing of $5,195. Data is available for 1 year (2020–2020), covering 2 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location St Petersburg, FL
- Active Since 06/10/2007
- Last Updated 11/08/2011
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1639372253
Products in Payments
- Hetlioz (Drug) $16.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in St Petersburg
Edward Braun, Md, MD
Family Medicine — Payments: $329,209
Dr. Robert Wallace, Md, MD
Family Medicine — Payments: $151,311
Dr. Frederic Guerrier, M.d, M.D
Family Medicine — Payments: $45,706
Dr. Gigi Lefebvre, Md, MD
Family Medicine — Payments: $15,802
Dr. Daniel Eckstein, M.d, M.D
Family Medicine — Payments: $10,665
Dr. Kunal Amin, Md, MD
Family Medicine — Payments: $10,623